Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children: Prospective, Multi-center, Randomize, Parallel Group Placebo Controlled Clinical Trial

Trial Profile

Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children: Prospective, Multi-center, Randomize, Parallel Group Placebo Controlled Clinical Trial

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Lactobacillus reuteri (Primary) ; Amoxicillin/clavulanic acid
  • Indications Diarrhoea
  • Focus Therapeutic Use
  • Acronyms PEARL
  • Most Recent Events

    • 25 Jul 2017 Planned End Date changed from 1 Jun 2018 to 1 Sep 2018.
    • 25 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2018.
    • 25 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top